187 related articles for article (PubMed ID: 15771616)
1. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Kodama Y; Asai N; Kawai K; Jijiwa M; Murakumo Y; Ichihara M; Takahashi M
Cancer Sci; 2005 Mar; 96(3):143-8. PubMed ID: 15771616
[TBL] [Abstract][Full Text] [Related]
2. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
3. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
4. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
[TBL] [Abstract][Full Text] [Related]
5. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
6. The RET proto-oncogene: a potential target for molecular cancer therapy.
Pützer BM; Drosten M
Trends Mol Med; 2004 Jul; 10(7):351-7. PubMed ID: 15242684
[TBL] [Abstract][Full Text] [Related]
7. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
Asai N; Jijiwa M; Enomoto A; Kawai K; Maeda K; Ichiahara M; Murakumo Y; Takahashi M
Pathol Int; 2006 Apr; 56(4):164-72. PubMed ID: 16634961
[TBL] [Abstract][Full Text] [Related]
8. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
9. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
10. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
Drosten M; Stiewe T; Pützer BM
Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
[TBL] [Abstract][Full Text] [Related]
11. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
de Groot JW; Links TP; Plukker JT; Lips CJ; Hofstra RM
Endocr Rev; 2006 Aug; 27(5):535-60. PubMed ID: 16849421
[TBL] [Abstract][Full Text] [Related]
12. Minireview: RET: normal and abnormal functions.
Santoro M; Melillo RM; Carlomagno F; Vecchio G; Fusco A
Endocrinology; 2004 Dec; 145(12):5448-51. PubMed ID: 15331579
[TBL] [Abstract][Full Text] [Related]
13. A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure.
Orgiana G; Pinna G; Camedda A; De Falco V; Santoro M; Melillo RM; Elisei R; Romei C; Lai S; Carcassi C; Mariotti S
J Clin Endocrinol Metab; 2004 Oct; 89(10):4810-6. PubMed ID: 15472167
[TBL] [Abstract][Full Text] [Related]
14. Expression, purification, and inhibition of human RET tyrosine kinase.
Mologni L; Sala E; Riva B; Cesaro L; Cazzaniga S; Redaelli S; Marin O; Pasquato N; Donella-Deana A; Gambacorti-Passerini C
Protein Expr Purif; 2005 May; 41(1):177-85. PubMed ID: 15802236
[TBL] [Abstract][Full Text] [Related]
15. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
16. RET tyrosine kinase signaling in development and cancer.
Arighi E; Borrello MG; Sariola H
Cytokine Growth Factor Rev; 2005; 16(4-5):441-67. PubMed ID: 15982921
[TBL] [Abstract][Full Text] [Related]
17. BAY 43-9006 inhibition of oncogenic RET mutants.
Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
[TBL] [Abstract][Full Text] [Related]
18. RET inhibition: implications in cancer therapy.
Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
[TBL] [Abstract][Full Text] [Related]
19. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
Santoro M; Carlomagno F
Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
[TBL] [Abstract][Full Text] [Related]
20. The RET proto-oncogene in human cancers.
Jhiang SM
Oncogene; 2000 Nov; 19(49):5590-7. PubMed ID: 11114739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]